# Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome

> **NCT02141035** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Alberta** · enrollment: 20 (actual)

## Conditions studied

- Carpal Tunnel Syndrome
- Compression Neuropathy

## Interventions

- **DRUG:** Acetyl-l-carnitine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02141035
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2017-06
- **Final completion:** 2017-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02141035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02141035, "Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02141035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*